Decision: Favourable
Study Title:
The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease
NREC Code:
22-NREC-CT-186
Decision:
Favourable
Meeting Date:
11/01/2023
Study Type:
CT Application
Principal Investigator:
Dr Maria Byrne
PI Institution:
Mater Misericordiae University Hospital
Sponsor:
Novo Nordisk Ltd